Status:
UNKNOWN
Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia
Lead Sponsor:
Johann Wolfgang Goethe University Hospital
Conditions:
Ataxia Telangiectasia
Eligibility:
All Genders
2-45 years
Phase:
NA
Brief Summary
Ataxia telangiectasia (A-T) is a rare devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer susceptibility. The immu...
Detailed Description
Ataxia teleangiectasia (A-T) is a rare devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer susceptibility. The imm...
Eligibility Criteria
Inclusion
- aim group: genetically and/or clinically diagnosed A-T
- age 2-45 years
- written informed consent
Exclusion
- age \< 2 or \> 45 years
- other diseases with influence on the immune system (i.e. diabetes mellitus, malignoma, dialysis-dependent renal failure)
Key Trial Info
Start Date :
October 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03357978
Start Date
October 1 2016
End Date
September 30 2019
Last Update
November 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital, Allergology, Pneumology and Cystic Fibrosis, Goethe University Frankfurt
Frankfurt am Main, Hesse, Germany, 60590